Identification of Resistance Biomarkers to HER2 Inhibitors

Iván González, Medical Oncologist at Comprehensive Oncology Center, Hospital Angeles Puebla, shared a post on X about a paper titled “Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer” published in MDPI.

Authors: Alvan Cai, Yuan Chen, Lily S. Wang, John K. Cusick and Yihui Shi.

“Identification of Resistance Biomarkers to HER2 Inhibitors: Advances and Challenges in HER2+ Breast Cancer.

• Therapeutic advances: HER2 inhibitors have significantly improved the treatment of HER2+ breast cancer.
• Persistent challenge: Resistance to these drugs remains a critical issue.
• Key biomarkers identified: Mutations in the ERBB2 gene, activation of alternative signaling pathways, expression of estrogen receptors, and alterations in regulatory protein levels have been found.
• New explorations: More effective regimens and promising combination therapies are being investigated.

This review highlights current HER2-targeted therapies, analyzes predictive biomarkers of drug resistance, and presents emerging therapies, especially combination treatments, aimed at overcoming resistance in the context of HER2+ breast cancer.”

Source: Iván González/X